INTRODUCTION
The RAS genes (NRAS, KRAS, and HRAS) encode 21-kDa proteins that are members of the superfamily of small GTP-binding proteins, which have diverse intracellular signaling functions including control of cell proliferation, growth, and apoptosis 1 . Somatic activating mutations in RAS are present in up to 30% of all human cancers 2 . Germline RAS pathway mutations have only recently been described as causing the related Costello (HRAS), Noonan (PTPN11, KRAS, SOS1), and cardiofaciocutaneous syndromes (KRAS, BRAF, MEK1, and MEK) [3] [4] [5] [6] [7] . Individuals with these syndromes typically present with severe developmental anomalies in various combinations of facial abnormalities, heart defects, short stature, skin and genital abnormalities, and mental retardation 8 .
Defects in the immune system have not been reported. Patients with Costello and Noonan syndromes have an increased propensity to solid and hematopoietic tumors, respectively 3, 8 . Germline mutations in NRAS have not yet been described.
The autoimmune lymphoproliferative syndrome (ALPS) (OMIM 601859/603909)
is the most common genetic disorder of lymphocyte apoptosis and is characterized by chronic accumulation of nonmalignant lymphocytes, defective lymphocyte apoptosis, and an increased risk for the development of hematological malignancies 9 . A signature of the disease is the accumulation of αβ T cells lacking the CD4 and CD8 coreceptors that are termed "double-negative" T cells (DNTs: CD4 − CD8 − TCRαβ + cells). These cells bear no known relationship to thymic DNTs, a stage that occurs before αβ TCR gene rearrangements in ontogeny 10 . According to genotype, ALPS can be classified as types Ia, Ib, and II, which are due to germline mutations in CD95 (TNFRSF6), CD95 ligand (TNFSF6), and caspase 10 (CASP10), respectively [11] [12] [13] [14] [15] . Additionally, somatic mutations of CD95 in αβ DNTs can also cause ALPS of type Im (mosaic) 16 . All of these mutations impair extrinsic, Fas receptor-mediated apoptosis. An enigma has been the ALPS individuals who have no defects in CD95 pathway apoptosis (some ALPS type III patients) 17 . This group encompasses a large number of individuals and is probably genetically heterogeneous. In an attempt to unveil new genetic defects, we investigated alternative apoptosis pathways in ALPS type III and identified one ALPS patient with a unique defect in cytokine withdrawal-induced apoptosis due to an activating somatic NRAS mutation affecting hematopoietic cells.
METHODS

Cells and treatments
Patients were studied under an NIH IRB approved ALPS research protocol after obtaining informed consent. Peripheral blood lymphocytes (PBL) were isolated by FicollHypaque gradient centrifugation, and cultured in RPMI-1640 media (supplemented with 2µM L-glutamine, 10 mM HEPES, 100 IU/ml penicillin, 100 µg/ml streptomycin, 10%
fetal bovine serum). PBL were activated with 1 µg/ml of anti-CD3 (OKT3, Ortho Biotech, Bridgewater, NJ) and 25 IU/ml of recombinant human IL-2 (Roche Applied Science, Indianapolis, IN) for 3 days. The activated cells were washed twice with PBS and cultured for at least 3 additional days in complete media supplemented with 100 IU/ml of IL-2. Cells were used for experiments between the 6th and 21st days in culture.
For cytokine withdrawal assays, IL-2-containing media was changed 24 h prior to experiments. The IL-2-treated cells were then washed 3 times with PBS and re-suspended at 1x106 cells/ml in complete media without IL-2 and cultured for different periods of were from Calbiochem.
Immunoblotting
Stimuli were terminated by addition of ice-cold PBS and cell pellets were lysed immediately with RIPA buffer (10 mM Tris-HCl pH 7.0, 150 mM NaCl, 0.1% NP40, The pellet (membrane fraction) was lysed using 3% SDS-containing RIPA buffer at room temperature for 30 min. The purity of cytosolic fraction was evaluated by blotting for mitochondrial cytochrome oxidase II or Ox P4.
Small-interfering RNA and transient transfections
Normal human PBL were separated and activated as described above. Activated PBL were transfected with either a small interfering oligonucleotide RNA (siRNA) or a scrambled non-silencing control oligo (nsRNA). siRNAs were designed online using the software BLOCK-iTTM RNAi designer from Invitrogen 
Active NRAS pull down
Active GTP-bound NRAS was immunoprecipitated using the EZ detection Ras activation kit (Pierce), according to the manufacture's protocol. The immunoprecipitated proteins were separated by SDS-PAGE and probed with an anti-NRAS antibody (F-155, Santa
Cruz).
DNA Sequencing
DNA samples were isolated from P58 and an unrelated, healthy individual (wild-type control). Selected regions of the following loci were amplified using puReTaq Ready-ToGo PCR beads (Amersham Biosciences, Piscataway, NJ): 
Microarray Analysis
RNA expression in lymphocytes from P58 was compared to that in 2 normal controls (NL1, NL2) at 0 and 24 hours post IL-2 withdrawal. Total RNA was extracted, reverse transcribed, biotin labeled, fragmented, and hybridized to human Affymetrix U133Plus2.0 microarrays following standard Affymetrix procedures (Affymetrix, Santa Clara, CA). After staining with streptavidin-phycoerythrin (Molecular Probes) and biotinylated anti-streptavidin antibody (Vector Laboratories), microarrays were scanned in the CCMD/CC Functional Genomics and Proteomics Facility using the Affymetrix GeneChip Scanner. Summary probe set intensities were computed from the resulting images using GCOS version 1.2 software. Results were deposited into the NIHLIMS database, then retrieved and analyzed using the MSCL Analyst's Toolbox (http://affylims.cit.nih.gov) and the JMP statistics package (SAS, Inc., Cary, NC).
Briefly, signal intensities were quantile-normalized and transformed using an adaptive variance stabilizing transform, termed "S10" 19 . A two-way ANOVA on time (0, 24 hr) and patient group (NL, P58) was performed on each gene. The difference between P58
and NL was calculated along with the significance of the patient group variable. Genes were selected if this difference was greater than two-fold and the change among the three patient groups reached P < 0.05, unadjusted. This resulted in a list of 205 probe sets, corresponding to 158 unique genes and 31 probe sets without usable annotations. A hierarchical cluster analysis on the difference from mean expression for the 205 probe sets was used to construct a heatmap and dendrogram, using the six samples from the NL and P58 groups, thus highlighting groups of similarly behaving genes. This gene list was then thematically explored using Ingenuity Pathways Analysis 3.0 (Ingenuity Systems).
RESULTS
Defective IL-2 Withdrawal-Induced Apoptosis in a Patient with Clinical and Laboratory
Hallmarks of ALPS
The intrinsic mitochondrial pathway of apoptosis can be triggered by developmental cues in the thymus or bone marrow, cytokine deprivation, DNA damage, or treatment with cytotoxic drugs 20, 21 . To screen for defects in this pathway, we exposed activated lymphocytes from individuals with salient features of ALPS (lymphadenopathy and increased αβ DNTs) but normal CD95-mediated apoptosis, to inducers of intrinsic apoptosis including staurosporine, γ-radiation, and cytokine withdrawal. We identified an individual whose lymphocytes clearly resisted death induced by IL-2 withdrawal (Fig.   1A ). Despite defective IL-2 withdrawal death, we found no abnormalities in apoptosis induced by an agonistic anti-APO-1 (CD95) antibody (Apo1.3), staurosporine, or γ-radiation (Fig. 1B-D) . Moreover, activated T cells did not spontaneously proliferate or secrete cytokines, but did show persistent proliferation after IL-2 withdrawal compared with normal cells (Fig 2. and data not shown) . Thus, lymphocytes from P58 demonstrated a specific defect in the intrinsic pathway of apoptosis. 
Figure 2. In vitro cellular proliferation and viability of P58 lymphocytes. (A) Activated lymphocytes from 4 normal donors (NL 1 to 4), an ALPS 1A patient and P58 were cultured in media containing 100 IU/ml of IL-2, and incorporation of [3H]-thymidine analyzed 18 h later. (B) Activated lymphocytes from NL1, NL2, an ALPS 1A patient and P58 were cultured as described in A and total cell numbers counted daily by flow cytometry. (C) [3H]-thymidine incorporation by activated lymphocytes from a NL and P58 that were cultured in media without IL-2 for 24h. (D) Activated lymphocytes from 3 normal donors (NL1-3), an ALPS 1A patient and P58 were cultured in media without IL-2 and cell death was measured by staining with propidium iodide (PI) and 3, 3'-dihexyloxacarbocyanine iodide (DiOC6) followed by flow cytometric analysis.
During cytokine withdrawal, the proapoptotic B cell lymphoma 2 (BCL-2) family members BAX and BAK are activated and oligomerize at mitochondrial surfaces, causing permeabilization of the outer membrane, which releases cytochrome c and triggers apoptosis 20, 21 . After IL-2 withdrawal, we found that P58 cells were markedly defective in BAX activation and mitochondrial cytochrome crelease, correlating with a decreased percentage of apoptotic nuclei compared with control cells after cytokine withdrawal, but not staurosporine treatment, clearly indicating a selective mitochondrial apoptosis defect ( Fig. 1E and F, and Fig. 3A and B
Figure 3. Analysis of cytosolic release of cytochrome c and AIF by subcellular fractionation. Immunoblotting of cytochrome c (Cyt C), apoptosis inducing factor (AIF), Cox IV, and β-actin in the cytosols of activated T lymphocytes from a NL, an ALPS 1A patient, and P58 that have been deprived of IL-2 for 72 h (A) or treated with 500 nM of staurosporine (STS) for 2 h (B). The degree of purity of the cytosolic fractions is demonstrated by probing with the mitochondrial proteins CoxIV (A) or OxP4 (B), CW, cytokine withdrawal.
Diminished BCL-2-Interacting Mediator of Cell Death (BIM) Levels in P58
Critical initiators of intrinsic apoptosis that act upstream of BAX and BAK are the BCL-2 homology 3 (BH3) subclass of the BCL-2 family 20 . Knockout mice lacking BIM, a BH3-only protein, manifest immune abnormalities including lymphocyte accumulation, autoimmunity, and various apoptosis defects, especially cytokine withdrawal-induced cell death 23 . We therefore measured BIM levels and found markedly reduced basal and induced levels after IL-2 withdrawal from activated T cells in P58 compared with normal or ALPS type 1A controls (Fig. 4A ). This defect was specific to BIM because other proapoptotic (PUMA, BAX) and antiapoptotic (BCL-2, BCL-X L , MCL-1) BCL-2 family members were unaffected (Fig. 4A) . We also observed a constitutive BIM deficiency in resting peripheral blood lymphocytes (PBLs) as well as purified T and B cells from P58
( Fig. 4B) .
In an additional effort to demonstrate the importance of BIM for mitochondrial apoptosis in human cells, we used small interfering RNA (siRNA) to silence BIM expression in otherwise normal human lymphocytes. BIM suppression caused resistance to IL-2 withdrawal-, but not Fas-or staurosporine-induced apoptosis, as seen in P58 (Fig.   4C and data not shown). Taken together, these data demonstrate that cells from P58 have a selective decrease of the proapoptotic protein BIM, which seems critical for cytokine withdrawal-induced apoptosis.
P58 Has a Gain-of-Function NRAS Mutation
To uncover the genetic basis of the BIM defect in P58, we sequenced the genomic locus of BIM and some of its regulators, including FOXO3a, FOXO1, FOXO4, ERK1/2, and JNK1/2, but found no mutations 20, 24 . We then carried out an unbiased screen by interrogating mRNA expression patterns in healthy controls and P58 lymphocytes at 0 and 24 h after IL-2 withdrawal by using microarrays. Two hundred and five probe sets were differentially expressed in P58 compared with controls ( Fig. 5A ; the microarray dataset is deposited in the GEO public database). Surprisingly, the gene expression pattern in P58 indicated the possible constitutive activation of the small GTPase, neuroblastoma RAS (NRAS) (Fig. 5B ). This included up-regulation of two dualspecificity phosphatases (DUSP4 and -6) that are inhibitors of ERK signaling and were previously shown to be overexpressed in tumor cell lines containing somatic activating mutations in NRAS 25 . We examined the nucleotide sequence of NRAS in P58 and found a single heterozygous G-to-A transition causing a nonconservative aspartic acid substitution for glycine at codon 13 (G13D) (Fig. 5C) . To exclude the possibility that this mutation was a somatic event, we analyzed genomic DNA from various cells and tissues including lymphoblasts, unseparated resting peripheral blood mononuclear cells, purified monocytes, EBV-transformed B cells generated years before the diagnosis, as well as buccal epithelial cells (Fig. 5C and data not shown) . The mutation was found in all hematopoietic samples but not in the epithelial cells, suggesting a somatic event affecting only the hematopoietic compartment. Accordingly, neither of the patient's parents, his sibling, or his two children harbored the mutant allele (data not shown). Importantly, the very same amino acid change in NRAS arises somatically in human pediatric and adult myeloid and lymphoid malignancies, but was never before documented in nonmalignant cells or tissues 26, 27 .
Mutations in codons 12, 13, and 61 are known to stabilize RAS proteins in an active, GTP-bound state by reducing intrinsic GTPase activity and causing resistance to GTPase-activating proteins 28, 29 . Consistent with the genetic alteration, we found that active NRAS was increased in P58 lymphocytes in serum-rich and, especially, in serumpoor conditions (Fig. 5D ). We therefore hypothesized that the "gain-offunction" NRAS mutation may result in hyperactivation of the RAS/RAF/ERK pathway, which can negatively regulate BIM expression [30] [31] [32] 
Hyperactive NRAS Induces BIM Down-Regulation Through ERK in Human Lymphocytes
To investigate the relationship between hyperactive NRAS and BIM suppression, we transfected human lymphocytes with wild-type (NRAS WT ) or mutant NRAS (NRAS G13D ).
Overexpression of NRAS WT and especially NRAS G13D reduced BIM in H-9 cells and primary normal human lymphocytes ( Fig. 6A and B) , reminiscent of HRAS overexpression in epithelial cells 33 . We consistently observed a 3-to 4-fold reduction in BIM, although this could be an underestimate of the effect because the transfection efficiency did not reach 100% in all cases.
Figure 5. Identification of a de novo gain-of-function NRAS mutation in P58. (A) Heat map and relational dendrogram results of a microarray study demonstrating the 205 probe sets differentially expressed by cells from P58 compared with cells from two normal subjects, NL1 and NL2. Activated lymphocytes were lysed at 0 and 24 h after IL-2 withdrawal, and mRNA expression was analyzed by using microarrays (B) Diagram demonstrating differential expression in P58 cells of genes in the NRAS/RAF/ERK pathway. Red and green arrows indicate the genes up-or down-regulated in P58, respectively, compared with controls. (C) Sequencing of NRAS by using genomic DNA from P58 lymphoblasts and monocytes demonstrating the heterozygous G-to-A, G13D substitution. (D) Active GTP-bound NRAS was immunoprecipitated before and after serum withdrawal in a NL and P58, by using a Raf-1 (RBD)-GST fusion protein as bait.
The total quantity of NRAS in cell lysates before immunoprecipitation is also shown. The most widely studied RAS effector proteins are either in the RAF/MEK/ERK pathway or the phosphatidylinositol 3-kinase pathway 1,2 . We found that chemical inhibition of MEK1, the MAP kinase kinase immediately upstream of ERK1/2, by using the drugs PD98059 or U0126 rescued BIM protein expression in P58 lymphocytes and NRAS-overexpressing H9 cells (Fig. 6C and data not shown) . Remarkably, ERK inhibition also restored apoptosis after IL-2 withdrawal in P58 lymphocytes (Fig. 6D ).
Figure 6. BIM down-regulation by NRAS through ERK. (A and B) Expression constructs for hemagglutinin (HA)-tagged wild type (WT) or active mutant (G13D) NRAS were transfected into the human lymphoid cell line H-9 (A) or primary human activated lymphocytes (B), followed 48 h later by quantification of BIM
Despite the strong increase in BIM protein levels after MEK inhibition, BIM mRNA varied little (Fig. 7A ), consistent with a posttranscriptional, rather than transcriptional, down-regulation of BIM by ERK. This was also true when resting lymphocytes from P58
were treated with MEK inhibitors in IL-2-rich conditions, and BIM protein and mRNA levels were measured ( Fig. 7B and C) . By contrast, the inhibitors LY294002 and wortmannin had no effect on BIM levels in P58 lymphocytes indicating that the phosphatidylinositol 3-kinase pathway was not involved (Fig. 7D and data not shown) .
Thus, active NRAS down-regulates BIM through the induction of the RAF/MEK/ERK pathway.
Correction of the Apoptotic Defect by Farnesylation Inhibition and NRAS Silencing
To further demonstrate the causative role of active NRAS in decreased BIM and defective lymphokine withdrawal apoptosis, we used two approaches. First, we used farnesyltransferase inhibitors (FTIs) that block the membrane localization and function of RAS proteins and are currently under clinical investigation for the treatment of human cancers 34 . Treatment with one such pharmaceutical, FTI-277, corrected the apoptotic defect and increased BIM levels in P58 lymphocytes (Fig. 8A) . This drug had a negligible effect on apoptosis and BIM levels in normal cells (Fig. 8A) .
Second, we decreased NRAS expression in P58 lymphocytes by using siRNA.
Each of three different siRNA oligonucleotides reduced NRAS expression and restored BIM levels and sensitivity to apoptosis in P58 cells ( Fig. 8B and C) . By contrast, NRAS siRNAs had no significant effect on BIM or sensitivity to IL-2 withdrawal in normal cells (data not shown). These results verify that the heterozygous mutation causes an abnormal gain-of-function that is reversed by silencing or functional inactivation of NRAS. (20 mM) for the difference between the BIM knockout mice and P58.
Figure 7. Effects of MEK1 and PI3K manipulation in P58 cells. (A) Activated lymphocytes from two NL and from P58 were deprived of IL-2 and treated with either the DMSO vehicle or MEK1 inhibitors PD98059 (PD)
The mechanism of BIM suppression under conditions of hyperactive NRAS is not clear. In other cellular models of hyperactive KRAS, BIM is down-regulated through phosphorylation, ubiquitination, and degradation by the proteasomal machinery 32 . Here, we show that BIM protein levels are severely depressed in resting and activated T cells from P58 compared with normals, despite equivalent basal mRNA levels. Additionally, the usual up-regulation of BIM mRNA after IL-2 withdrawal was impaired in cells from P58. Also, BIM protein returned to almost normal levels on MEK/ERK blockage, but mRNA remained the same. In our preliminary experiments (data not shown), there was no change in BIM levels on proteasomal blockade in lymphocytes from P58. Taken together, these data suggest a double mechanism for BIM suppression via hyperactive NRAS: inhibition of up-regulation of mRNA and translational inhibition, but this remains to be formally shown. Our new understanding of NRAS suggests that RAS antagonists such as FTIs could have beneficial effects on disorders of lymphocyte homeostasis and autoimmunity in addition to cancer.
